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Background: Pseudomonas aeruginosa is known to be a multidrug resistant opportunistic pathogen. Particularly,
P. aeruginosa PAO1 polyphosphate kinase mutant (ppk1) is deficient in motility, quorum sensing, biofilm formation
and virulence.
Findings: By using Phenotypic Microarrays (PM) we analyzed near 2000 phenotypes of P. aeruginosa PAO1 polyP
kinase mutants (ppk1 and ppk2). We found that both ppk mutants shared most of the phenotypic changes and
interestingly many of them related to susceptibility toward numerous and different type of antibiotics such as
Ciprofloxacin, Chloramphenicol and Rifampicin.
Conclusions: Combining the fact that ppk1 mutants have reduced virulence and are more susceptible to
antibiotics, polyP synthesis and particularly PPK1, is a good target for the design of molecules with anti-virulence
and anti-persistence properties.
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Multidrug resistanceFindings
Pseudomonas aeruginosa is a major opportunistic patho-
gen frequently involved in hospital-acquired infections
and can produce severe pneumonia, burn wound infec-
tions, and sepsis. Particularly, multidrug resistant (MDR)
variants are emerging rapidly in the clinic for this patho-
gen. In addition, P. aeruginosa resistance rates have in-
creased to available antimicrobial agents, limiting the
choice of available anti-infective chemicals [1]. Looking
for alternatives with economic and human health im-
pact, new antimicrobial agents with novel biological tar-
gets or strategies are desperately needed to combat
highly resistant P. aeruginosa infections [2,3]. Current
original strategies combine the reduction of bacterial* Correspondence: fpchavez@uchile.cl
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unless otherwise stated.virulence with a simultaneous increase of animal host
defence, instead of eradicating the pathogen [4,5].
Inorganic polyphosphate (polyP) are essential for bac-
terial resilience during stress and stringencies, cellular
motility, biofilm formation and virulence [6]. Many bac-
terial pathogens knockout of polyP synthesis gene (ppk1)
result in cellular defects, particularly in the context of
virulence toward the host they invade [6,7]. Specifically,
a Pseudomonas aeruginosa PAO1 mutant of polyP syn-
thesis (Pappk1) was impaired in motility, biofilm devel-
opment, quorum sensing and virulence in ocular and
burned-mouse models [8,9]. Moreover, this mutant ex-
hibited reduced viability after exposure to a β-lactam
antibiotic [10]. Similar results were reported in ppk1
mutants from S. typhimurium and S. dublin that used
Polymyxin B15 antibiotic [11]. In addition to homo-
logues of PPK1, another widely conserved polyP enzyme
is PPK2, which, in contrast to the ATP-dependent polyP
synthetic activity of PPK1, preferentially catalyses theentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Venn Diagrams derived from the Phenotype MicroArrays
results of P. aeruginosa PAO1 polyP synthesis mutants. The numbers
indicate the total phenotypes gained or lost for the wild type strain
compared with the mutant strains ppk1 (left) and ppk2 (right).
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GDP [12]. The fact that polyP is involved in bacterial
virulence and resilience processes makes it an attractive
target for antimicrobial agents [2].
To provide a more complete analysis of P. aeruginosa
polyP synthesis mutants (ppk1 and ppk2) phenotypes and
to obtain greater insight into the physiological changes
and particularly chemical susceptibility we used Pheno-
type Microarray (PM) technology [13]. Biolog Phenotype
MicroArrays studies in Pseudomonas aeruginosa PAO1
have been used to facilitate further characterization of
known mutation strains and for testing bioinformatic pre-
dictions for mutations in hypothetical or unknown genes
[14]. We used P. aeruginosa polyphosphate synthesis
knockout mutants ppk1 (PA5242) and ppk2 (PA0141)
from a P. aeruginosa Mini- Tn5-Tcr gene knockout mu-
tants collection [15]. We confirmed by PCR both muta-
tions and bacterial cell suspensions from all strains were
inoculated into each of the 20 PM plates for full metabolic
profiling according to standard protocols recommended
by Biolog Inc. for Pseudomonas strains [14,16]. The PM
plates were located in an aerobic OmniLog incubator
reader set at 30°C which collected data every 15 min over
a 72-h period. PM tests were conducted in duplicate, and
the plates were also examined visually at the end of each
incubation period for independent confirmation. The
OmniLog® V. 1.5 comparison module and the average
height parameter were used for data analysis with stand-
ard thresholds for detection. A consensus graphical pro-
files for all metabolic and sensitivity tests for each mutant
were generated using two independent runs (Additional
file 1: Figure S1).
For visualization and clustering data analysis, Multiex-
periment Viewer (MeV version 4.6) software was used.
MeV is part of the TM4 Microarray Software Suite, an
open source system for statistical and clustering analysis
of omics data [17].
Comparing the metabolic and sensitivity capabilities
between mutants and their isogenic parent strains we
show that both mutant strains behave similar in nutrient
utilization (PM1-10) and sensitivity to chemicals (PM11-
20) assays (Figure 1, Table 1). This indicates that these
two strains shared most of the phenotypic patterns and
differed only in a few features (Figure 1, Additional file
2: Tables S1-S4). Particularly interesting is the altered
isoleucine metabolism found exclusively in the ppk1 mu-
tant (Additional file 2: Table S2). In Pseudomonas per-
sistence of ppk1 mutant in the stationary phase was
significantly affected [18,19]. In contrast, the main meta-
bolic pathways were not significantly influenced by the
loss of ppk1 as revealed from respiration patterns of the
ppk mutants in phenotypic microarrays. Our results are
in agreement with those reported in Pseudomonas putida
KT2440 where accumulation of inorganic polyphosphateenables stress endurance and catalytic vigour but the major
metabolic routes were not significantly influenced by the
loss of ppk1 [18].
The respiration patterns of P. aeruginosa PAO1 ppk1
and ppk2 associated with the metabolism of carbon
(PM1-PM2), nitrogen (PM3), phosphorous and sulfur
(PM4) sources were relatively moderate as compared to
previous unpublished PM results from our laboratory
with Δppk1 mutant from Escherichia coli (Additional file
1: Figures S2 and S3). We speculate that the apparent
metabolic robustness in Pseudomonas ppk1 mutant is
due to in the E. coli genome there is only one gene
orthologous to the PPK1 protein [12]. In contrast, in
Pseudomonas aeruginosa PAO1 the presence of another
ortholog (PPK2) can compensate the lost of ppk1 gene,
in fact, despite the absence of detectable PPK1 activity
(<1% of wild type), Δppk1 mutants still possess as much
as 20% of polyP of the wild type levels [12].
Our results show that the majority of phenotypic
changes observed were coincident in ppk1 and ppk2
mutants (Figure 1, Table 1). We found only few differ-
ences among phenotypes between both ppk mutants
(Additional file 2: Tables S1-S4). We were able to iden-
tify novel phenotypes for polyP synthesis mutants in
P. aeruginosa PAO1 and found that both mutants are
susceptible to multiple antibiotics (Figure 2).
Table 1 Summary of P. aeruginosa PAO1 polyP synthesis mutants (ppk1 and ppk2) common gain and lost phenotypes
Test ppk1 difference ppk2 difference Mode of action
Gain phenotype Gain phenotype
L-Arginine 50 75 C-Source, carboxylic acid
His-Met 61 56 N-Source, peptide
Carbenicillin 158 71 Wall, lactam
Cefsulodin 80 80 Wall, cephalosporin
Ruthenium red 78 110 Respiration, mitochondrial Ca2+ porter
Erythromycin 67 80 Protein synthesis, 50S ribosomal subunit, macrolide
Lost phenotype Lost phenotype
D-Gluconic acid −112 −106 C-Source, carboxylic acid
D-Mannitol −68 −57 C-Source, carbohydrate
L-Valine −60 −58 N-Source, amino acid
L-Methionine Sulfone −69 −95 S-Source, organic
Orphenadrine −78 −146 Anti-cholinergic
Patulin −534 −495 Microtubulin polymerization inhibitor, antifungal
2,2′-Dipyridyl −401 −397 Chelator, lipophilic
Sodium Arsenite −332 −242 Toxic anion
Sodium Arsenate −305 −321 Toxic anion, P04 analog
Dichlofluanid −271 −119 Fungicide, phenylsulphamide
Thiamphenicol −269 −193 Protein synthesis, amphenicol
Chloramphenicol −209 −173 Protein synthesis, amphenicol
Chlorodinitrobenzene −182 −187 Oxidizes sulfhydryls, depletes glutathione
8-Hydroxyquinoline −181 −230 Chelator, lipophilic
Nafcillin −163 −172 Wall, lactam
Antimony (III) chloride −158 −153 Toxic cation
1,10-Phenanthroline monohydrate −152 −171 Chelator, lipophilic
Captan −152 −113 Fungicide, carbamate
Sulfathiazole −148 −172 Folate antagonist, PABA analog
Gallic acid −141 −115 Respiration, ionophore, H+
Poly-L-lysine −140 −63 Membrane, detergent, cationic
Protamine sulfate −129 −109 Membrane, nonspecific binding
Sulfadiazine −127 −107 Folate antagonist, PABA analog
Oxacillin −124 −130 Wall, lactam
Myricetin −113 −122 DNA & RNA synthesis, polymerase inhibitor
Nickel chloride −113 −80 Toxic cation
Plumbagin −106 −118 Oxidizing agent
Oxophenylarsine −99 −161 Tyrosine phosphatase inhibitor
trans-Cinnamic acid −98 −90 Respiration, ionophore, H+
EDTA −67 −88 Chelator, hydrophilic
Glycine hydroxamate −66 −136 tRNA synthetase
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antibiotic families with different mechanisms of action
such as Penicillins (Nafcillin, Oxacillin), Ansamycins
(Streptomycin), Sulfonamides (Sulfadiazine, Sulfathia-
zole) and Others (Chloramphenicol, Thiamphenicol). Toconfirm this finding, we used two additional well-
established methods for antimicrobial susceptibility test-
ing. The results from the M.I.C.Evaluator™ (Oxoid) and
Etest® (Biomeriux) corroborated the susceptibility of ppk
mutants observed in the PM results (Additional file 2:
Chemical sensitivity (PM11 to PM20)
Figure 2 PolyP kinases (ppk1 and ppk2) mutants from P. aeruginosa PAO1 are susceptible to multiple antibiotics. Clustering analysis of chemical
sensitivity tests (PM11-20) from P. aeruginosa PAO1 ppk1 and ppk2 mutants. Gain (blue) and lost (yellow) phenotypes were standardized by
dividing the respiration values of the mutants by the respective values of the wild type strain, for each phenotype.
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parameters for both ppk mutants were particularly inter-
esting for the antibiotics Rifampicin, Imipinen and Cip-
rofloxacin, either because Pseudomonas is intrinsically
resistant or because recent strains highly resistant to
these antibiotics have been found recently [20]. It should
be noted that concentrations of antibiotics used in the
PM experiments are set according to the minimal inhibi-
tory concentration for E. coli. It is possible that other
antibiotic susceptibilities have not been detected since
both the control strain and the mutants were resistant.
Taking into account that various bacterial regulatory
genes that participate in complex regulatory networkshave been reported to influence both virulence and anti-
biotic resistance [20], polyP levels could affect regulators
that control both antibiotic resistance and virulence.
Finally, our results support the recent finding that bac-
terial persistence, a phenomenon in which isogenic pop-
ulations of antibiotic-sensitive bacteria produce rare cells
that transiently become multidrug tolerant, is affected in
ppk1 deficient strain [21]. This small fraction of cells
that grow slowly explains bacterial antibiotic tolerance
because the cellular targets disturbed by lethal antibi-
otics are much less vulnerable in slow-growing than in
fast-growing cells. This is important because the pres-
ence of persister cells has been suggested to be one of
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chronic diseases. Indeed, clinical isolates of Pseudo-
monas aeruginosa from cystic fibrosis patients show an
increase in high persistence mutants the longer that
these isolates remain in the host. This indicates that per-
sistence plays a major role in the failure to remove these
bacterial populations from the cystic fibrosis lung [20].
Consequently, polyP synthesis, and particularly PPK1,
in bacterial pathogens exhibits a potential target for anti-
microbial drug design because combines the reduction
of bacterial virulence and persistence, while simultaneously
increasing susceptibility to antibiotics as we describe here
by using PM technology. This could positively impact the
host health for clearing the bacterial infection. Considering
that no PPK1 homologs have been identified in higher-
order eukaryotes [22], our phenotypic sensibility results
highlight the importance of polyP synthesis as a putative
target for the treatment of this opportunistic bacterium.
Additional files
Additional file 1: Figure S1. Consensus graphical profile of metabolic
and sensitivity tests of P. aeruginosa ppk1 (A) and ppk2 (B) mutants.
Significant changes are enclosed in boxes. Yellow indicates that
respiration rate of the wild type and mutant strains were similar. Red
indicates faster respiration rate of the wild type (lost phenotype). Green
indicates faster respiration rate of the mutant (gain phenotype). The
quantitative difference values are shown in Table 1 and Supplementary
tables. Figure S2. Clustering analysis of metabolic tests (PM1-PM8) and
pH response (PM10) from P. aeruginosa PAO1 ppk1 and ppk2 mutants.
Gain (blue) and lost (yellow) phenotypes were standardized by dividing
the respiration value of the mutants by the value of the wild type strain,
for each phenotype. The results are shown separately for the different
categories: carborn (C) sources, nitrogen (N) sources, phosphorus (P) and
sulfur sources (S), peptide nitrogen (N) sources and pH response.
Figure S3. Venn diagrams of phenotypic microarrays results from polyP
synthesis mutants from E. coli K12 and P. aeruginosa PAO1. The numbers
indicate the total phenotypes gained (A) or lost (B) between P.
aeruginosa ppk1 and ppk2 mutants and E. coli Δppk1 mutant. Phenotypic
microarray results from E. coli Δppk1 mutant were performed in a
previous work (Unpublished results).
Additional file 2: Table S1. Summary of P. aeruginosa ppk1 mutant
gain and lost phenotypes. Table S2. Summary of P. aeruginosa ppk2
mutant gain and lost phenotypes. Table S3. Summary of unique P.
aeruginosa ppk1 mutant gain and lost phenotypes. Table S4. Summary
of unique P. aeruginosa ppk2 mutant gain and lost phenotypes. Table S5.
Summary of antimicrobial susceptibility testing (M.I.C.Evaluator™(Oxoid) and
Etest® (Biomeriux) for P. aeruginosa ppk1 and ppk2 mutant strains.
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